Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 9.19

(-3.26%)

Operating Income Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual operating income in 2023 was -31.71 Million PLN , down -28.78% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly operating income in 2024 Q2 was 486 Thousand PLN , up 110.56% from previous quarter.
Pure Biologics Spólka Akcyjna reported an annual operating income of -24.62 Million PLN in 2022, down -134.96% from previous year.
Pure Biologics Spólka Akcyjna reported an annual operating income of -10.48 Million PLN in 2021, up 9.29% from previous year.
Pure Biologics Spólka Akcyjna reported a quarterly operating income of -4.6 Million PLN for 2024 Q1, up 53.3% from previous quarter.
Pure Biologics Spólka Akcyjna reported a quarterly operating income of -6.25 Million PLN for 2023 Q3, up 32.81% from previous quarter.

Annual Operating Income Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual Operating Income of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	Operating Income	Operating Income Growth
2023	-31.71 Million PLN	-28.78%
2022	-24.62 Million PLN	-134.96%
2021	-10.48 Million PLN	9.29%
2020	-11.55 Million PLN	-164.62%
2019	-4.36 Million PLN	-592.05%
2018	-631.01 Thousand PLN	-63.37%
2017	-386.24 Thousand PLN	7.92%
2016	-419.45 Thousand PLN	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	486 Thousand PLN	110.56%
2024 Q1	-4.6 Million PLN	53.3%
2023 Q3	-6.25 Million PLN	32.81%
2023 Q4	-9.85 Million PLN	-57.73%
2023 Q1	-6.3 Million PLN	13.61%
2023 Q2	-9.3 Million PLN	-47.46%
2023 FY	-31.71 Million PLN	-28.78%
2022 Q2	-5.53 Million PLN	-1.47%
2022 Q4	-7.3 Million PLN	-15.05%
2022 FY	-24.62 Million PLN	-134.96%
2022 Q1	-5.45 Million PLN	-2798.02%
2022 Q3	-6.34 Million PLN	-14.77%
2021 Q1	-3.06 Million PLN	31.04%
2021 FY	-10.48 Million PLN	9.29%
2021 Q3	-4.1 Million PLN	-16.84%
2021 Q4	202 Thousand PLN	104.92%
2021 Q2	-3.51 Million PLN	-14.79%
2020 Q4	-4.44 Million PLN	-75.56%
2020 FY	-11.55 Million PLN	-164.62%
2020 Q2	-2.5 Million PLN	-59.69%
2020 Q3	-2.52 Million PLN	-0.92%
2020 Q1	-1.56 Million PLN	19.37%
2019 Q2	-1.18 Million PLN	-261.63%
2019 Q1	-329 Thousand PLN	-43.02%
2019 FY	-4.36 Million PLN	-592.05%
2019 Q4	-1.94 Million PLN	-115.85%
2019 Q3	-901.75 Thousand PLN	24.21%
2018 Q3	-233.81 Thousand PLN	-124.41%
2018 FY	-631.01 Thousand PLN	-63.37%
2018 Q1	-62.97 Thousand PLN	11.83%
2018 Q2	-104.19 Thousand PLN	-65.45%
2018 Q4	-230.04 Thousand PLN	1.61%
2017 Q3	211.78 Thousand PLN	0.0%
2017 FY	-386.24 Thousand PLN	7.92%
2017 Q4	-71.41 Thousand PLN	-133.72%
2016 FY	-419.45 Thousand PLN	0.0%

Peer Operating Income Comparison of Pure Biologics Spólka Akcyjna

Name	Operating Income	Operating Income Difference
Bioceltix S.A.	-15.81 Million PLN	-100.499%
BIOTON S.A.	15.29 Million PLN	307.375%
Captor Therapeutics Spolka Akcyjna	-73.01 Million PLN	56.56%
Mabion S.A.	55.06 Million PLN	157.605%
Molecure S.A.	-22.1 Million PLN	-43.496%
NanoGroup S.A.	-7.9 Million PLN	-301.397%
Pharmena S.A.	34.87 Million PLN	190.958%
Poltreg S.A.	-16.86 Million PLN	-88.103%
Ryvu Therapeutics S.A.	-100.94 Million PLN	68.58%
Synthaverse S.A.	8.64 Million PLN	466.809%
Urteste S.A.	-6.44 Million PLN	-391.981%